HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Cohance Lifesciences gets nod to make $10 million investment in NJ Bio Inc
Dec-03-2025

Cohance Lifesciences has received approval for the fund infusion by way of investment in compulsorily convertible preferred stock of NJ Bio Inc, USA, a subsidiary of the company, upto an amount of $10 million. The fund when deployed will be used by the said subsidiary to support its growth initiatives including capex.

The board of directors of the company in its meeting held on December 02, 2025 considered and approved the same.

Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.

  RELATED NEWS >>